Back to results
US 2002/0161015 A1Published application
Ophthalmic composition
AssigneeR-Tech Ueno, Ltd.
InventorsRyuji Ueno, Ichie Kato
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeR-Tech Ueno, Ltd.
InventorsRyuji Ueno, Ichie Kato
Estimating the term…
The ophthalmic composition of this invention are used for treatment of diabetic corneal lesion and/or for treatment of deteriorated corneal esthesia, which comprises, as an active ingredient, a compound represented by the general formula (I): 1 wherein A and B are independently lower alkylene, X, Y, and Z are independently halogen, or a pharmacologically acceptable salt thereof. In addition, the ophthalmic composition of this invention are used for treatment of non-diabetic corneal lesion, for treatment of dry eye syndrome, and/or for treatment of hypolacrimation which comprises, as an active ingredient, an aldose reductase inhibitor. The ophthalmic compositions of this invention are effective for treatment of at least one disease selected among corneal lesion, deteriorated corneal esthesia, dry eye syndrome, and hypolacrimation.
An ophthalmic composition for treatment of diabetic corneal lesion and/or for treatment of deteriorated corneal esthesia which comprises, as an active ingredient, a compound represented by the general formula (I):
An ophthalmic composition for treatment of non-diabetic corneal lesion which comprises, as an active ingredient, an aldose reductase inhibitor.
An ophthalmic composition for treatment of dry eye syndrome which comprises, as an active ingredient, an aldose reductase inhibitor.
An ophthalmic composition for treatment of hypolacrimation which comprises, as an active ingredient, an aldose reductase inhibitor.
A method for treating diabetic corneal lesion and/or deteriorated corneal esthesia which comprises administering an effective amount of a compound represented by the general formula (I):
A method for treating non-diabetic corneal lesion which comprises administering an effective amount of an aldose reductase inhibitor to a subject in need of a treatment of non-diabetic corneal lesion.
A method for treating dry eye syndrome which comprises administering an effective amount of an aldose reductase inhibitor to a subject in need of a treatment of dry eye syndrome.
A method for treating hypolacrimation which comprises administering an effective amount of an aldose reductase inhibitor to a subject in need of a treatment of hypolacrimation.
Use of a compound represented by the general formula (I):
Use of an aldose reductase inhibitor in the manufacture of an ophthalmic composition for the treatment of non-diabetic corneal lesion.
Use of an aldose reductase inhibitor in the manufacture of an ophthalmic composition for the treatment of dry eye syndrome.
Use of an aldose reductase inhibitor in the manufacture of an ophthalmic composition for the treatment of hypolacrimation.
Dependencies are inferred from the claim text.